HN

Hindiskere Narashimhaiah Bhagya

Active Director Director DIN 11477821
DIN 11477821 First appointment Jan 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Hindiskere Narashimhaiah Bhagya

Data last updated:

Hindiskere Narashimhaiah Bhagya is a Director at Maagnex Pharmaceuticals Private Limited (since 2026). The company operates in Pharma.

DIN 11477821
Primary Designation Director
Industry Pharma
First Appointment 12 Jan 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director12 Jan 20262026Active

Board colleagues of Hindiskere Narashimhaiah Bhagya

NameDINCompanyDesignation
Basavarajaiah Manasa11477820Maagnex Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Maagnex Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Hindiskere Narashimhaiah Bhagya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hindiskere Narashimhaiah Bhagya

Hindiskere Narashimhaiah Bhagya currently holds 1 directorship: Maagnex Pharmaceuticals Private Limited (Director, since 12 Jan 2026).

Hindiskere Narashimhaiah Bhagya was first appointed on 12 Jan 2026 as Director at Maagnex Pharmaceuticals Private Limited.

The current boards of Hindiskere Narashimhaiah Bhagya's companies include Basavarajaiah Manasa (Maagnex Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available